are they banning tirzepatide FDA says the weight-loss drug shortage is over The pharmaceutical manufacturers of both

Patients in the UK who are interested in accessing retatrutide through a clinical trial can search for active studies via the NIHR 'Be Part of Research' website (bepartofresearch.nihr.ac.uk) or the ClinicalTrials.gov database

Significant progress has been made in clinical trials for potential treatments, including obeticholic acid (OCA), elafibranor, resmetirom, semaglutide and pegozafermin

Most patients begin at 0.25 mg once weekly, then progress by 0.25 mg increments every four weeks until reaching a therapeutic dose between 1.0 mg and 2.4 mg weekly

Patients with complex medical histories, unexplained symptoms, pregnancy considerations, immune disorders, active cancer concerns, severe allergies, medication interactions, or competitive sport obligations should avoid self-directed use and seek medical guidance